Abstract

Research Article

Aripiprazole-induced seizures in children with autism spectrum disorder and epilepsy

Mohammed MS Jan*

Published: 31 January, 2020 | Volume 3 - Issue 1 | Pages: 008-010

Purpose: Children with autism spectrum disorder are at an increased risk for developing seizures, which can be triggered by classical antipsychotics. Aripiprazole is an atypical antipsychotic that has a safer drug profile. The objective is to present the experience with seizure control in autistic children who are placed on Aripiprazole.

Methods: Series of consecutive autistic children with comorbid epilepsy treated with Aripiprazole were identified prospectively over a 3-year period. Monthly follow up by one pediatric neurologist was performed to document seizure control.

Results: 56 autistic children with comorbid epilepsy were placed on Aripiprazole. Most children (59%) were seizure free for at least 6 months. The initial Aripiprazole dose was 5 mg in all patients. Follow up ranged between 5-8 months (mean 6.9). A total of 5 (9%) children developed seizure provocation (3/5) or worsening seizure control (2/5). There were 3 males and 2 females with ages ranging between 6-11.5 years (mean 8.5). Three of these children had a previous history of seizure worsening with other antipsychotic drugs (respiridone in 2 and haloperidol in 1). One child with seizure provocation developed status epilepticus 5 days after introducing Aripiprazole that required intensive care admission. The drug was stopped in all 5 children with no long-term effects.

Conclusion: Seizure provocation or worsening seizure control is not uncommon following the introduction of Aripiprazole in autistic children with controlled epilepsy. Although the risk is low, parents should be warned and advised on what to do, particularly in the first month of therapy.

Read Full Article HTML DOI: 10.29328/journal.japch.1001009 Cite this Article Read Full Article PDF

Keywords:

Aripiprazole; Seizure; Epilepsy; Child; Side effect; Autism

References

  1. Ditcher AM, Brodie MJ. New antiepileptic drugs: a review. N Engl J Med. 1996; 334: 1583-1590. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8628341
  2. Velíšková J, Silverman JL, Benson M, Lenck-Santini PP. Autistic traits in epilepsy models: Why, when and how? Epilepsy Res. 2018; 144: 62-70. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29783181
  3. Kumar B, Prakash A, Sewal RK, Medhi B, Modi M. Drug therapy in autism: a present and future perspective. Pharmacol Rep. 2012; 64: 1291-1304. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23406740
  4. Parmeggiani L, Belmonte A, Ferrari AR, Perucca E, Guerrini R. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study. J Child Neurol. 2000; 15: 671-674. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11063081
  5. Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2009; 18: 250-260. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19718428
  6. Thabet FI, Sweis RT, Joseph SA. Aripiprazole-induced seizure in a 3-year-old child: a case report and literature review. Clin Neuropharmacol. 2013: 36; 29-30. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23334073
  7. Bolton PF, Carcani-Rathwell I, Hutton J, Goode S, Howlin P, et al. Epilepsy in autism: features and correlates. Br J Psychiatry. 2011; 198: 289-294. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21972278
  8. Strasser L, Downes M, Kung J, Cross JH, Haan MD. Prevalence and risk factors for autism spectrum disorder in epilepsy: a systematic review and meta-analysis. Dev Med Child Neurol. 2018; 60: 19-29. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29119560
  9. Wu CS, Wang SC, Yeh IJ, Liu SK. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry. 2016; 77: e573-579. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27249081

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More